Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban.

Eikelboom JW, Connolly SJ.

Cardiol Res. 2015 Jun;6(3):267-277. doi: 10.14740/cr413w. Review.

2.

Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.

Venker BT, Ganti BR, Lin H, Lee ED, Nunley RM, Gage BF.

J Arthroplasty. 2017 Feb;32(2):645-652. doi: 10.1016/j.arth.2016.09.033. Review.

PMID:
27823844
3.

Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.

Freeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, Al-Ahmad A, Turakhia MP.

Circ Arrhythm Electrophysiol. 2016 Jun;9(6). pii: e003407. doi: 10.1161/CIRCEP.115.003407.

PMID:
27307517
4.

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.

Sié P.

Drug Des Devel Ther. 2016 May 18;10:1683-9. doi: 10.2147/DDDT.S94167. Review.

5.

Update on Anticoagulation: What the Interventional Radiologist Needs to Know.

Kamath SD, McMahon BJ.

Semin Intervent Radiol. 2016 Jun;33(2):122-31. doi: 10.1055/s-0036-1582124. Review.

PMID:
27247481
6.

How we treat bleeding associated with direct oral anticoagulants.

Marano G, Vaglio S, Pupella S, Liumbruno GM, Franchini M.

Blood Transfus. 2016 Sep;14(5):465-73. doi: 10.2450/2016.0180-15. Review.

7.

Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting.

Rosencher N, Samama CM, Feuring M, Brueckmann M, Kleine E, Clemens A, Frostick S.

Thromb J. 2016 Apr 1;14:8. doi: 10.1186/s12959-016-0082-4.

8.

Meta-analysis and suggested guidelines for prevention of venous thromboembolism (VTE) in foot and ankle surgery.

Calder JD, Freeman R, Domeij-Arverud E, van Dijk CN, Ackermann PW.

Knee Surg Sports Traumatol Arthrosc. 2016 Apr;24(4):1409-20. doi: 10.1007/s00167-015-3976-y. Review.

9.

Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.

Vaglio S, Prisco D, Biancofiore G, Rafanelli D, Antonioli P, Lisanti M, Andreani L, Basso L, Velati C, Grazzini G, Liumbruno GM.

Blood Transfus. 2016 Jan;14(1):23-65. doi: 10.2450/2015.0172-15. No abstract available.

10.

The evolution of anticoagulant therapy.

Franchini M, Liumbruno GM, Bonfanti C, Lippi G.

Blood Transfus. 2016 Mar;14(2):175-84. doi: 10.2450/2015.0096-15. Review.

11.

Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery.

Wurnig C, Clemens A, Rauscher H, Kleine E, Feuring M, Windhager R, Grohs J.

Thromb J. 2015 Nov 26;13:37. doi: 10.1186/s12959-015-0066-9.

12.

Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials.

Eriksson BI, Dahl OE, Rosencher N, Clemens A, Hantel S, Feuring M, Kreuzer J, Huo M, Friedman RJ.

Thromb J. 2015 Nov 17;13:36. doi: 10.1186/s12959-015-0067-8.

13.

Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience.

King AE, Szarlej DK, Rincon F.

Neurohospitalist. 2015 Oct;5(4):234-44. doi: 10.1177/1941874415569069. Review.

14.

Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice.

Preusch MR, Ieronimakis N, Wijelath ES, Cabbage S, Ricks J, Bea F, Reyes M, van Ryn J, Rosenfeld ME.

Drug Des Devel Ther. 2015 Sep 10;9:5203-11. doi: 10.2147/DDDT.S86969.

15.

Using a Systems Pharmacology Model of the Blood Coagulation Network to Predict the Effects of Various Therapies on Biomarkers.

Nayak S, Lee D, Patel-Hett S, Pittman DD, Martin SW, Heatherington AC, Vicini P, Hua F.

CPT Pharmacometrics Syst Pharmacol. 2015 Jul;4(7):396-405. doi: 10.1002/psp4.50.

16.

Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V.

Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Fukuzawa M, Abe K, Tachibana S.

Thromb J. 2015 Aug 12;13:27. doi: 10.1186/s12959-015-0057-x.

17.

Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.

Fanola CL.

Vasc Health Risk Manag. 2015 May 27;11:271-82. doi: 10.2147/VHRM.S62595. Review.

18.

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.

Douxfils J, Tamigniau A, Chatelain B, Goffinet C, Dogné JM, Mullier F.

Thromb J. 2014 Nov 4;12:24. doi: 10.1186/1477-9560-12-24. Review.

19.

More indications approved and safety news for dabigatran etexilate.

Cinteza M.

Maedica (Buchar). 2014 Dec;9(4):405-7. No abstract available.

20.

Pharmacological prevention of venous thromboembolism in orthopaedic surgery.

Prisco D, Cenci C, Silvestri E, Emmi G, Ciucciarelli L.

Clin Cases Miner Bone Metab. 2014 Sep;11(3):192-5. Review.

Supplemental Content

Support Center